BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Salbutamol HFA-152a readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Salbutamol HFA-152a\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06433921-3559@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Salbutamol HFA-152a: Phase 1 readout est. (NCT06433921)
DESCRIPTION:Salbutamol HFA-152a\, phase 1\, Asthma.\nStudy: A Study to Comp
 are the Relative Potency of Salbutamol Administered Via Metered Dose Inhal
 ers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics A
 ged 18 to 65 Inclusive\nEstimated primary completion: 16 April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/salbutamol-hfa-152a#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06433921
URL:https://assetmemo.bio/drug/salbutamol-hfa-152a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
